Cingulate extends CMO Matthew Brams' trial period to Dec 31, 2026 at $400,000 base salary

Cingulate Inc.

Amendment No. 2 to the employment agreement of Matthew N. Brams, EVP and Chief Medical Officer, extends his Trial Period from September 30, 2026 to December 31, 2026.
Brams' annual base salary is set at $400,000 for 100% full-time effort, effective January 1, 2026 through December 31, 2026.
At the end of the Trial Period, CEO Shane J. Schaffer has sole discretion to keep Brams full-time or return him to a part-time role at a lower base salary.
All other provisions of the January 1, 2026 employment agreement remain unchanged.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.